Detailed Information
Cited 29 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
- Authors
- Cho, B. C.; Lee, K. H.; Cho, E. K.; Kim, D-W.; Lee, J-S.; Han, J-Y.; Kim, S-W.; Spira, A.; Haura, E. B.; Sabari, J. K.; Sanborn, R. E.; Bauml, J. M.; Gomez, J. E.; Lorenzini, P.; Infante, J. R.; Xie, J.; Haddish-Berhane, N.; Thayu, M.; Knoblauch, R. E.; Park, K.
- Issue Date
- Sep-2020
- Publisher
- ELSEVIER
- Citation
- ANNALS OF ONCOLOGY, v.31, pp.S813 - S813
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 31
- Start Page
- S813
- End Page
- S813
- ISSN
- 0923-7534
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Cho, Eun Kyung
- College of Medicine (Department of Medicine)